Resuscitation
Volume 81, Issue 1 , Pages 47-52 , January 2010

Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia

  • Tsuyoshi Shiga

      Affiliations

    • Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 3 3353 8111; fax: +81 3 3356 0441.
    • ,
  • Keiji Tanaka

      Affiliations

    • Intensive and Cardiac Care Unit, Nippon Medical School, Tokyo, Japan
    • ,
  • Rinya Kato

      Affiliations

    • Department of Cardiology, Nagoya Ekisaikai Hospital, Nagoya, Japan
    • ,
  • Mari Amino

      Affiliations

    • Department of Cardiology, Tokai University School of Medicine, Isehara, Japan
    • ,
  • Yuji Matsudo

      Affiliations

    • Department of Cardiology, Kimitsu Chuo Hospital, Kisarazu, Japan
    • ,
  • Toshihiro Honda

      Affiliations

    • Department of Cardiology, Saisei-kai Kumamoto Hospital, Kumamoto, Japan
    • ,
  • Koichi Sagara

      Affiliations

    • Department of Cardiology, The Cardiovascular Institute, Tokyo, Japan
    • ,
  • Atsushi Takahashi

      Affiliations

    • Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
    • ,
  • Takao Katoh

      Affiliations

    • Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
    • ,
  • Mitsuyoshi Urashima

      Affiliations

    • Division of Molecular Epidemiology, Jikei University School of Medicine, Tokyo, Japan
    • ,
  • Satoshi Ogawa

      Affiliations

    • International University of Health and Welfare Mita Hospital, Tokyo, Japan
    • ,
  • Teruo Takano

      Affiliations

    • Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
    • ,
  • Hiroshi Kasanuki

      Affiliations

    • Faculty of Science and Engineering, Waseda University, Tokyo, Japan
    • ,
  • for the Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study Investigators

Received 6 June 2009 ,Revised 15 August 2009 ,Accepted 20 September 2009.

References 

  1. 2005 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 7.2. Management of cardiac arrest. Circulation. 2005;112:IV-58–IV-66
  2. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871–878
  3. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884–890
  4. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol. 1993;109:157–163
  5. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol. 1992;58:107–115
  6. Isomoto S, Konoe A, Centurión OA, et al. Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent. Pacing Clin Electrophysiol. 1995;18:2022–2027
  7. Onishi S, Kasanuki H, Shoda M, et al. Efficacy of intravenous doses of MS-551 for drug-resistant sustained ventricular tachycardia. J Clin Ther Med. 1997;13:1759–1771[in Japanese, English abstract]
  8. Shiga T, Shoda M, Matsuda N, et al. Electrophysiological characteristic of a patient exhibiting the short-coupled variant of torsade de pointes. J Electrocardiol. 2001;34:271–275
  9. Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias. Post-marketing special investigation. Circ J. 2005;69:1237–1243
  10. Amino M, Yoshioka K, Iwata O, et al. Efficacy of nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest. J Cardiol. 2003;41:127–134[in Japanese, English abstract]
  11. Shimizu K, Sugita M, Kuroki T, et al. The effectiveness of nifekalant for out-of-hospital cardiopulmonary arrest with intractable ventricular fibrillation. J Jpn Soc Intensive Care Med. 2004;11:105–110[in Japanese, English abstract]
  12. Igarashi M, Fujino T, Toyoda M, et al. Defibrillation effects of nifekalant in patients with out-of-hospital ventricular fibrillation. Pacing Clin Electrophysiol. 2005;28:S155–S157
  13. Yoshioka K, Amino M, Morita S, et al. Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)? Comparative study of out-of-hospital CPA with acidosis and in-hospital CPA without acidosis. Circ J. 2006;70:21–27
  14. Tahara Y, Kimura K, Kosuge M, et al. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J. 2006;70:442–446
  15. Kovoor P, Love A, Hall J, et al. Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia. Intern Med J. 2005;35:518–525
  16. Katoh T, Tsunoo M, Mitsuhashi T, et al. Phase I study of MS-551 (I): a single intravenous injection study. J Clin Ther Med. 1997;13:1659–1674[in Japanese, English abstract]
  17. Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation. 2000;102:2665–2670
  18. Kerber RE, Pandian NG, Jensen SR, et al. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: experimental studies. J Am Coll Cardiol. 1986;7:397–405
  19. Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs. 2008;68:607–630
  20. Zhou L, Chen BP, Kluger J, Fan C, Chow MSS. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol. 1998;31:1672–1678
  21. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation?. J Am Coll Cardiol. 1997;29:688–692
  22. Simon RD, Sturdivant JL, Leman RB, Wharton JM, Gold MR. The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin Electrophysiol. 2009;32:24–28
  23. Zhong JQ, Dorian P. Epinephrine and vasopressin during cardiopulmonary resuscitation. Resuscitation. 2005;66:263–269
  24. Weaver WD, Fahrenbruch CE, Johnson DD, Hallstrom AP, Cobb LA, Copass MK. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation. 1990;82:2027–2034
  25. van Walraven C, Stiell IG, Wells GA, Hébert PC, Vandemheen K. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The OTAC study group. Ann Emerg Med. 1998;32:544–553

☆ A Spanish translated version of the abstract of this article appears as Appendix in the online version at doi:10.1016/j.resuscitation.2009.09.027.

PII: S0300-9572(09)00503-6

doi: 10.1016/j.resuscitation.2009.09.027

Resuscitation
Volume 81, Issue 1 , Pages 47-52 , January 2010

Article Tools